Amgen Inc. (AMGN)
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies
Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses. Recent financials show solid revenue growth and improved margins, though net selling prices and legacy drugs like Enbrel remain under pressure. Valuation analysis reveals AMGN is priced for no growth, offering 27% upside if the company achieves even modest revenue increases.
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Avoid These Dividend Disasters Before It's Too Late
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen Inc. (AMGN) BofA Securities 2025 Healthcare Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN ) BofA Securities 2025 Healthcare Conference Call May 14, 2025 12:20 PM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research and Development Conference Call Participants Tim Anderson - Bank of America Merrill Lynch Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. large pharma and biotech analyst at Bank of America.
